As the daughter of an air force officer and a nurse, I am fascinated by defence systems. There is none more impressive than the human immune system, equipped as it is with a rich arsenal to defend against different types of pathogen. Viruses have evolved to trick, bypass and evade these defences. Our immune systems have, in turn, learned to recognise and deter these virus stealth tactics. In Covid-19, the enemy is a tiny piece of genetic material wearing a lipid coat and a protein crown.
So how is our immune system able to defend against viral infections, and how does this apply to Covid-19? The virus that causes Covid-19 is called severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2), and was first detected in humans around five months ago. It is a coronavirus. Corona, in Latin, means crown. The virus is adorned with an outer layer of protein covered in spikes, like a crown. These spikes help the virus attach itself to target cells. The research community is fast learning about immunity to Covid-19, and we are also applying our knowledge of similar respiratory viruses to predict what to expect in this infection.
Importantly, Covid-19 cannot gain entry to our homes or bodies by itself we have to let it in
Think of a virus as a robot; it cannot reproduce so it needs a factory of materials proteins, lipids and nucleotides to build copies of itself. The coat allows the virus to attach itself to the target cells membrane. The virus then fuses with the cell and releases a shopping list of instructions on how to build and assemble new viruses. This shopping list, the virus genome, is written in nucleotides (RNA). The first job of a virus that enters our bodies is to invade target cells so that it can comfortably remove its coat and deploy its RNA.
Once inside, the virus commandeers the cell and borrows cellular machinery to build more viruses before immune cells detect the intruders and raise the alarm. Antibody proteins that are able to stick to the virus-spike proteins, and prevent attachment to the target cells, are called neutralising antibodies: generating them is often the goal of protective vaccination.
Our infected cells make the ultimate sacrifice and invite their own destruction by displaying distress signals for T-cells, which swiftly detect and kill them. T-cells are cytotoxic powerful serial killers that can recognise peptide fragments of virus displayed on the infected cell surface. When they do, they release a payload of toxic enzymes that kill the infected cell in a kiss of death. This strategic martyrdom is organised by the immune system to deprive the virus of its replication factories and can lead to the reduction of viral load in the patient. It takes several days for antiviral T-cells to expand and antibodies to be generated. Heres the silver lining: memory cells ensure that if we encounter the same virus again, we can react immediately with pre-existing defences. Sars-Cov-2 is new to humanity so we have no protective immunological memory. Vaccines prepared using harmless parts of the virus can help us build protective memory.
The viruss enemy superpower is spreading. The virus achieves this through shedding from infected patients. Sars-Cov-2 is expert at hopping from person to person, and in some people, it achieves a stealthy existence with mild or no symptoms. Once many copies of the virus are made, it needs to jump to another host. It hitches a ride on droplets that can be coughed or sneezed to a distance of up to two metres. Droplets can survive on surfaces for several hours enabling pick-up by a new host, or they can be directly inhaled if another person is in close proximity. Studies are emerging into animal hosts so far the virus has been detected in a few ferrets, cats, tigers and dogs. No animal deaths have yet been reported, and we dont know if animals can transmit back to humans.
The age differential in fatalities for Covid-19 suggests, with some exceptions, that a healthy immune system is usually able to control infection. Meanwhile, an ageing or weakened immune system may struggle to deploy a protective arsenal. Importantly, Sars-Cov-2 cannot gain entry to our homes or bodies by itself we have to let it in. This is why official advice has centred around cleaning our hands and avoiding touching our faces.
We know that a healthy immune system is usually able to eliminate infection in a couple of weeks. However, we have no understanding of the components of our immune arsenal that contribute to this feat: some vaccines work by creating potent neutralising antibodies; other vaccines generate powerful memory T-cells. Antiviral antibodies emerge as early as three to four days after virus detection, but are they protective against future reinfection? We believe that antibodies to other coronaviruses (Sars, Mers) last from one to three years. Because this is a new virus, we dont yet know the answer to this question. Public Health England is recruiting 16,000 to 20,000 volunteers to monitor antibodies once a month for six to 12 months to confirm whether we can generate long-lasting antibody responses to Sars-Cov-2. Determining the quality of these antibodies will be important to understanding long-term protection.
What is our most potent immune weapon against Covid-19? Cytotoxic T-cells may play an important role. Immunologists and virologists are working together to discover the correlates of protection, to design vaccines that offer long-term defences against Covid-19. Years of investment in research means that we can use existing approaches to respond to this new threat, and early mobilisation of research funders, philanthropists and academics are diverting resources to bolster these efforts on an unprecedented scale. Experience has taught us that vaccines are able to eradicate infections from this planet (for instance, smallpox), and medicines against viruses that dont embed their genetic material to our own (for example, hepatitis C) can also achieve this.
Our secret weapon is research. Scientists are working hard on understanding Covid-19, and collaboration is key to this effort. But until a vaccine or treatment is available, we ought to work hard to protect ourselves and our families: isolate and prevent transmission by using physical distancing, face masks and sensible hygiene. If we all do our part, this little virus holding the world to ransom wont stand a chance.
Zania Stamataki is a senior lecturer and researcher in viral immunology at the University of Birmingham
Read the rest here:
Here's how your body gains immunity to coronavirus - The Guardian
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]